Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

NCT00553150 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00553150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00553150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
March 31, 2009
Completion date
November 15, 2019
Enrollment
122 (actual)
Sites
178

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors